Given that PPARγ was suppressed in stromal cell types by tumor-secreted factors in our in vitro models, we hypothesized that tumor development in a mouse xenograft model would limit the antitumor efficacy of rosiglitazone, a potent PPARγ agonist. This evidence concerns the gene PPARG and neoplasm.